Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
Pfizer said it still plans to release phase two trial data on a once-a-day version of its weight loss drug, known as danuglipron, in mid-2024.
Similar Posts
Rheinmetall forecasts sales to nearly double by 2026
Post Content Post Views: 69
Oil Markets on Alert: OPEC+ May Tighten the Taps Amidst Surplus Forecasts
Post Content Post Views: 52
Hashing It Out: A conversation about spot Bitcoin ETFs and decentralized ETFs
Post Content Post Views: 53
Azuki DAO rebrands to ‘Bean’ as it drops lawsuit against founder
Post Content Post Views: 48
Timbercreek Financial Corp. declares $0.0575 dividend
Post Content Post Views: 56
VCIG signs LoI to acquire AI enhanced-augmented reality gamification marketing platform
Post Content Post Views: 58